Hu et al. discovered that the truncated form of human epidermal growth factor receptor 2 (HER2), called p95HER2, drives tumor progression and resistance to the antibody–drug conjugate trastuzumab deruxtecan in HER2+ breast cancer. Blocking p95HER2 restores antitumor immunity.
- Dong Hu
- Xiaoshuang Lyu
- Peter C. Lucas
